Treatment of primary Sjögren syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 284-285

  Meijer, J M ^a,b   Pijpe, J ^a   Vissink, A ^a   Kallenberg, C G M ^b   Bootsma, H ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; SJOEGREN SYNDROME; TREATMENT DURATION; RETREATMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RETREATMENT; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 58849136715     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.092601     Document Type: Letter

References (3)

1. Pijpe J, van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
2. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007;46:626-30.
3. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic iupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.